

10/533300 HB
JC17 Rec'd PCT/PTO 29 APR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MEDER *et al.*

Appl. No.: (to be assigned; U.S. National

Phase of PCT/EP2003/011799

Int'l Filing Date: October 24, 2003

For: **Human Chondroosteomodulin
(TIG2), Production, and Use for the
Treatment or Diagnosis of Bone
Diseases, Cartilage Diseases,
Obesity, Inflammatory Diseases,
and Skin Diseases**

Confirmation No.: (to be assigned)

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 2388.0010000/SRL/BLS

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the cited documents are provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Agent for Applicants
Registration No. 50,893

Date: APRIL 29, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

10/4533300

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>			ATTY. DOCKET NO. 2388.0010000/SRL/BLS		APPLICATION NO. U.S. National Phase of PCT/EP2003/011799		
			FIRST NAMED INVENTOR Meder et al.				
			INT'L FILING DATE October 24, 2003		ART UNIT (to be assigned)		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 03/006996 A2	01/23/2003	WIPO			Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	1	Adams, A.E. et al., "1,25 Dihydroxyvitamin D3 and Dexamethasone Induce the Cyclooxygenase 1 Gene in Osteoclast-Supporting Stromal Cells," <i>J. Cell. Biochem.</i> 74:587-595, Wiley-Liss, Inc. (1999)				
	AS	1	Database Embl, Accession No. Q99969, Nagpal, S. et al., (created 2000, last updated October 2003)				
	AT	1	Meder, W. et al., "Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23," <i>FEBS Letts.</i> 555:495-499, Elsevier B.V. (first available online November 17, 2003; published December 18, 2003)				
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 2388.0010000/SRL/BLS	10453300 APPLICATION NO. U.S. National Phase of PCT/EP2003/011799
		FIRST NAMED INVENTOR Meder et al.	
		INT'L FILING DATE October 24, 2003	ART UNIT (to be assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2						Yes No
	AM2						Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	2	Methner, A. et al., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed during Bone Development," <i>Biochem. Biophys. Res. Comm.</i> 233:336-342, Academic Press (1997)
AS	2	Nagpal, S. et al., "Tazarotene-induced Gene 2 (TIG2), a Novel Retinoid-Responsive Gene in Skin," <i>J. Invest. Dermatol.</i> 109:91-95, The Society for Investigative Dermatology, Inc. (1997)
AT	2	Samson, M. et al., "ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains," <i>Eur. J. Immunol.</i> 28:1689-1700, Wiley-VCH Verlag GmbH, Germany (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 2388.0010000/SRL/BLS		APPLICATION NO. U.S. National Phase of PCT/EP2003/011799			
		FIRST NAMED INVENTOR Meder et al.					
		INT'L FILING DATE October 24, 2003		ART UNIT (to be assigned)			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Schulz-Knappe, P. et al., "Peptide bank generated by large-scale preparation of circulating human peptides," <i>J. Chromatography A</i> 776:125-132, Elsevier Science B.V. (1997)
	AS	3	Wittamer, V. et al., "Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids," <i>J. Exp. Med.</i> 198:977-985, The Rockefeller University Press (October 6, 2003)
	AT	3	International Search Report for International Patent Application No. PCT/EP2003/011799, mailed May 27, 2004, European Patent Office
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			